Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21724992 | 0.97 | MEN1 (0.33) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| Oxalic Acid SCHEMBL30335549 | 0.89 | MEN1 (0.33) | MEN1CYP2C9KMT2A | |
| SCHEMBL23210045 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL30845954 | 0.82 | — | — | |
| SCHEMBL3464319 | 0.82 | CRBN (0.41) | MEN1CYP2C9KMT2ACRBN | |
| Trifluoroacetic Acid SCHEMBL29397368 | 0.82 | — | — | |
| SCHEMBL30335542 | 0.79 | CYP2D6 (0.38) | CYP2C9TRIM24TRIM33CRBNALDH1A1 | |
| SCHEMBL9171769 | 0.78 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL4129906 | 0.76 | NEK2 (0.37) | MEN1CYP2C9KMT2ACRBNALDH1A1 | |
| SCHEMBL307414 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321599-B | Synthesis method of drug intermediate 7-oxo-2-azaspiro [3.5] nonane | 合肥远志医药科技开发有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-116981669-B | Pyrimidine or pyrido heterocyclic adenosine receptor inhibitor, preparation method and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-117881679-A | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117136187-A | Novel anti-hepatitis B compound | 上海齐鲁制药研究中心有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| CN-116981669-A | Pyrimidine or pyrido heterocyclic adenosine receptor inhibitor, preparation method and application thereof | 上海齐鲁制药研究中心有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023056589-A1 | MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-01 | — | — | US | disclosed |
| CN-115023267-A | Spirocyclic androgen receptor protein degrading agents | 密歇根大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| EP-4031241-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | The Regents Of The University Of Michigan (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-111943946-B | Dihydroquinazinone carboxylic acid compound containing nitrogen heterocyclic segment and application thereof | 中国医学科学院医药生物技术研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055756-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020200191-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020147702-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | MEN1 2537/4885CYP2C9 3385/4885KMT2A 683/4885 |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, NR5A1, ESRRA | MEN1 659/4885CYP2C9 857/4885KMT2A 1043/4885 |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | MEN1 4649/4885CYP2C9 66/4885KMT2A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.